

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

YAM 2 0013

U.S. APPLICATION NO. 09/002,424, 37 CFR 1.5

10/018924

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/JP00/04166

23 June 2000

23 June 1999

TITLE OF INVENTION COMPOSITION FOR PROMOTING PASSIVE EXTENSION OF BLADDER
SMOOTH MUSCLE

APPLICANT(S) FOR DO/EO/US

YANAGITA, Toshihiko

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
- a. ☐ is attached hereto (required only if not communicated by the International Bureau).
- b. ☒ has been communicated by the International Bureau.
- c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
- a. ☒ is attached hereto.
- b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
- a. ☐ are attached hereto (required only if not communicated by the International Bureau).
- b. ☐ have been communicated by the International Bureau.
- c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
- d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:

Application Data Sheet
Sequence Listing (12 pages)
Verified Statement Under 37 CFR
1.821(e)

Patent Label No. KL 8526933X US
December 19, 2001
 That _____
 for 87 Chrysler Drive, Edison, New Jersey 08839-3201
 Assistant Commissioner for Patents, Washington, D.C. 20231.

Laurie A. Boyle
(TYPED OR PRINTED NAME OF SENDER)

LAURIE A. BOYLAN

10/018924

U.S. APPLICATION NO. (PCT/US 1.17)

INTERNATIONAL APPLICATION NO.
PCT/JP00/04166ATTORNEY'S DOCKET NUMBER
YAM 2 001321. ☐ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO \$1040.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$890.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 890.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE | \$ |
|---|--------------|--------------|------------|----|
| Total claims | 14 - 20 = | 0 | x \$18.00 | \$ |
| Independent claims | 3 - 3 = | 0 | x \$84.00 | \$ |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable) | | | + \$280.00 | \$ |

TOTAL OF ABOVE CALCULATIONS =

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above
are reduced by 1/2.

SUBTOTAL = \$ 890.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

TOTAL NATIONAL FEE = \$ 890.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

TOTAL FEES ENCLOSED = \$ 930.00

Amount to be
refunded: \$
charged: \$

- a. ☒ A check in the amount of \$ 930.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 06-0308 A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. Credit card
information should not be included on this form. Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Richard M. Klein
FAY, SHARPE, FAGAN, MINNICH & McKEE, LLP
1100 Superior Avenue, Seventh Floor
Cleveland, OH 44114
RKlein@faysharpe.com
(216) 861-5582

SIGNATURE

Richard M. Klein
NAME

33,000

REGISTRATION NUMBER

10 01 924
531 Rec'd PCT 19 DEC 2001

I hereby certify that this Preliminary Amendment is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: BOX Patent Application, Assistant Commissioner of Patents, Washington, D.C. 20231.

Laurie A. Boylan
By: Laurie A. Boylan

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
YANAGITA, Toshihiko)

International Application No. PCT/JP00/04166)
International Filing Date June 23, 2000)

For: COMPOSITION FOR PROMOTING PASSIVE)
EXTENSION OF BLADDER SMOOTH MUSCLE)

Attorney Docket No. YAM 2 0013)

Cleveland, Ohio 44114
December 19, 2001

PRELIMINARY AMENDMENT

BOX Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Prior to the examination of the merits and/or calculation of the fees, kindly amend the above-identified application as follows:

IN THE CLAIMS:

Please amend claims 8, 9, and 10 to read as follows:

8. (Amended) A composition according to claim 1, wherein the C-terminus of the adrenomedullin is amidated.
9. (Amended) A composition according to claim 1, wherein Gly is added to the C-terminus of the adrenomedullin.

10. (Amended) A composition according to claim 1, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.


REMARKS

Entry of this preliminary amendment is requested at the U.S. Patent and Trademark Office's earliest convenience.

Respectfully submitted,

FAY, SHARPE, FAGAN,
MINNICH & McKEE, LLP

By:



Richard M. Klein
Reg. No. 33,000
1100 Superior Avenue
Seventh Floor
Cleveland, Ohio 44114
Telephone: 216-861-5582
Facsimile: 216-241-1666
E-mail: rklein@faysharpe.com

Attachment - Version With Markings to Show Changes Made

lab429a.wpd

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please amend claims **8, 9 and 10** (i.e. additions are underlined and deletions are bracketed) to read as follows:

IN THE CLAIMS:

8. (Amended) A composition according to [any of claims 1 and 4 to 7] claim 1, wherein the C-terminus of the adrenomedullin is amidated.

9. (Amended) A composition according to [any of claims 1 and 4 to 7] claim 1, wherein Gly is added to the C-terminus of the adrenomedullin.

10. (Amended) A composition according to [any of claims 1 and 4 to 7] claim 1, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.

10/018924

531 Rec'd PCI/P

19 DEC 2001

"EXPRESS MAIL" Mailing Label Number EL852683386USDate of Deposit: December 19, 2001

I hereby certify that this Verified Statement Under 37 C.F.R. § 1.821(f) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Laurie A. Boylan
Laurie A. Boylan

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|-------------------------------|---|--|
| IN RE APPLICATION OF | : | YANAGITA, Toshihiko |
| FOR | : | COMPOSITION FOR PROMOTING PASSIVE EXTENSION OF BLADDER SMOOTH MUSCLE |
| SERIAL NO. | : | Unknown |
| FILED | : | Herewith |
| INTERNATIONAL APPLICATION NO. | : | PCT/JP00/04166 |
| INTERNATIONAL FILING DATE | : | 23 JUNE 2000 |
| ATTORNEY DOCKET NO. | : | YAM 2 0013 |
| | | Cleveland, Ohio 44114-2518 December 19, 2001 |

VERIFIED STATEMENT UNDER 37 C.F.R. § 1.821(f)**Box Patent Application**

Assistant Commissioner for Patents

Washington, DC 20231

Dear Sir:

Herewith is a verified statement declaring that the information recorded on the enclosed diskette is identical to the information written sequence listing.

1. I hereby state that the information recorded in computer readable form is identical to the written sequence listing as required under 37 C.F.R. § 1.821(f).


2. I hereby state that the submission filed in accordance with 37

C.F.R. § 1.821(g), herein does not include new matter or matter which goes beyond the disclosure in the international application.

Respectfully submitted,

FAY, SHARPE, FAGAN
MINNICH & MCKEE, LLP

Date: 12/19/2001



Richard M. Klein
Reg. No. 33,000
1100 Superior Avenue, 7th Floor
Cleveland, Ohio 44114-2516
(216) 861-5582

PCT10

RAW SEQUENCE LISTING

DATE: 01/17/2002

PATENT APPLICATION: US/10/018,924

TIME: 07:15:17

Input Set : A:\S0042PCTSEQ.txt

Output Set: N:\CRF3\01172002\J018924.raw

ENTERED

2 <110> APPLICANT: Shionogi & Co., Ltd
4 <120> TITLE OF INVENTION: Composition for promoting passive extension of bladder
smooth muscle
W--> 5 <130> FILE REFERENCE: S0042PCT
C--> 7 <140> CURRENT APPLICATION NUMBER: US/10/018,924
C--> 8 <141> CURRENT FILING DATE: 2001-12-19
9 <150> PRIOR APPLICATION NUMBER: JP P1999-177549
10 <151> PRIOR FILING DATE: 1999-06-23
12 <160> NUMBER OF SEQ ID NOS: 6
14 <170> SOFTWARE: PatentIn Ver. 2.0
16 <210> SEQ ID NO: 1
17 <211> LENGTH: 1457
18 <212> TYPE: DNA
19 <213> ORGANISM: Homo sapiens
21 <220> FEATURE:
22 <221> NAME/KEY: CDS
23 <222> LOCATION: (165)..(719)
25 <220> FEATURE:
W--> 26 <221> NAME/KEY: mat peptide
27 <222> LOCATION: (447)..(602)
29 <400> SEQUENCE: 1
30 ggcacgagct ggatagaaca gctcaagcct tgccaactcg ggcctctcac tgcagctggg 60
32 cttggaacttc ggagttttgc cattgccagt gggacgtctg agactttctc cttcaagtac 120
34 ttggcagatc actctcttag cagggtctgc gcttcgcagc cggg atg aag ctg gtt 176
35 Met Lys Leu Val
37 tcc gtc gcc ctg atg tac ctg ggt tcg ctc gcc ttc cta ggc gct gac 224
38 Ser Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe Leu Gly Ala Asp
39 -90 -85 -80 -75
41 acc gct cgg ttg gat gtc gcg tcg gag ttt cga aag aag tgg aat aag 272
42 Thr Ala Arg Leu Asp Val Ala Ser Glu Phe Arg Lys Lys Trp Asn Lys
43 -70 -65 -60
45 tgg gct ctg agt cgt ggg aag agg gaa ctg cgg atg tcc agc agc tac 320
46 Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Met Ser Ser Ser Tyr
47 -55 -50 -45
49 ccc acc ggg ctc gct gac gtg aag gcc ggg cct gcc cag acc ctt att 368
50 Pro Thr Gly Leu Ala Asp Val Lys Ala Gly Pro Ala Gln Thr Leu Ile
51 -40 -35 -30
53 cgg ccc cag gac atg aag ggt gcc tct cga agc ccc gaa gac agc agt 416
54 Arg Pro Gln Asp Met Lys Gly Ala Ser Arg Ser Pro Glu Asp Ser Ser
55 -25 -20 -15
57 ccg gat gcc gcc cgc atc cga gtc aag cgc tac cgc cag agc atg aac 464
58 Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn
59 -10 -5 -1 1 5
61 aac ttc cag ggc ctc cgg agc ttt ggc tgc cgc ttc ggg acg tgc acg 512
62 Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe Gly Thr Cys Thr
63 10 15 20
65 gtg cag aag ctg gca cac cag atc tac cag ttc aca gat aag gac aag 560
66 Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/018,924

DATE: 01/17/2002

TIME: 07:15:17

Input Set : A:\S0042PCTSEQ.txt

Output Set: N:\CRF3\01172002\J018924.raw

```

67          25          30          35
69 gac aac gtc gcc ccc agg agc aag atc agc ccc cag ggc tac ggc cgc 608
70 Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln Gly Tyr Gly Arg
71          40          45          50
73 cgg cgc cgg cgc tcc ctg ccc gag gcc ggc cgg ggt cgg act ctg gtg 656
74 Arg Arg Arg Arg Ser Leu Pro Glu Ala Gly Pro Gly Arg Thr Leu Val
75          55          60          65          70
77 tct tct aag cca caa gca cac ggg gct cca gcc ccc ccg agt gga agt 704
78 Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro Pro Ser Gly Ser
79          75          80          85
81 gct ccc cac ttt ctt taggatttag gcgcccatgg tacaaggaat agtcgcgcaa 759
82 Ala Pro His Phe Leu
83          90
85 gcatcccgct ggtgectccc gggacgaagg acttcccgag cgggtgtgggg accggggctct 819
87 gacagccctg cggagaccct gagtccggga gccaccgctc gccggcgagc tctggcttgg 879
89 caaggccccc tcctctcggg ggcctcgctt ccttagcctt gctcagggtgc aagtgcccca 939
91 gggggcgggg tgacagaagaa tccgagtgtt tgccaggctt aaggagagga gaaactgaga 999
93 aatgaatgct gagacccccg gagcaggggt ctgagccaca gccgtgctcg cccacaaact 1059
95 gatctctcac ggcgtgtcac cccaccaggg cgcaagcctc actattactt gaactttcca 1119
97 aaacctaaag aggaagaagt caatgcgtgt tgtacataca gaggttaacta tcaattattta 1179
99 agtttgttgc tgtcaagatt tttttgttaa cttcaaatat agaatatttt ttgtacgtta 1239
101 tatattgtat taagggcatt ttaaagcaa ttatattgtc ctccctcatt ttaagcgtg 1299
103 aatgtctcag cgaggtgttaa agttgttcgc gcggtggaat gtgagtgtgt ttgtgtgcat 1359
105 gaaagagaaa gactgattac ctctgtgtgt gaagaaggaa acacogagtc tctgtataat 1419
107 ctattttacat aaaatgggtg atatgcgaac agcaaacc 1457
110 <210> SEQ ID NO: 2
111 <211> LENGTH: 185
112 <212> TYPE: PRT
113 <213> ORGANISM: Homo sapiens
115 <400> SEQUENCE: 2
116 Met Lys Leu Val Ser Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe
117          -90          -85          -80
119 Leu Gly Ala Asp Thr Ala Arg Leu Asp Val Ala Ser Glu Phe Arg Lys
120          -75          -70          -65
122 Lys Trp Asn Lys Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Met
123          -60          -55          -50
125 Ser Ser Ser Tyr Pro Thr Gly Leu Ala Asp Val Lys Ala Gly Pro Ala
126          -45          -40          -35
128 Gln Thr Leu Ile Arg Pro Gln Asp Met Lys Gly Ala Ser Arg Ser Pro
129          -30          -25          -20          -15
131 Glu Asp Ser Ser Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg
132          -10          -5          -1          1
134 Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe
135          5          10          15
137 Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr
138          20          25          30
140 Asp Lys Asp Lys Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln
141          35          40          45          50
143 Gly Tyr Gly Arg Arg Arg Arg Ser Leu Pro Glu Ala Gly Pro Gly

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/018,924

DATE: 01/17/2002

TIME: 07:15:17

Input Set : A:\S0042PCTSEQ.txt

Output Set: N:\CRF3\01172002\J018924.raw

```

144          55          60          65
146 Arg Thr Leu Val Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro
147          70          75          80
149 Pro Ser Gly Ser Ala Pro His Phe Leu
150          85          90
153 <210> SEQ ID NO: 3
154 <211> LENGTH: 1493
155 <212> TYPE: DNA
156 <213> ORGANISM: Sus scrofa
158 <220> FEATURE:
159 <221> NAME/KEY: CDS
160 <222> LOCATION: (148)..(711)
162 <220> FEATURE:
W--> 163 <221> NAME/KEY: mat peptide
164 <222> LOCATION: (430)..(585)
166 <400> SEQUENCE: 3
167 gcggaacagc tcgagccttg ccacctctag ttctttacca cagcttggag gtcgggggttt 60
169 tgccactgcc agagggacgt ctacagattc atcttcccaa atcttggcag atcacccct 120
171 tagcagggtc tgcacatctc agcggg atg aag ctg gtt ccc gta gcc ctg atg 174
172          Met Lys Leu Val Pro Val Ala Leu Met
173          -90
175 tac ctg gcc tcg ctc gcc ttc ctg gcc gct gac aca gct cgg ctc gac 222
176 Tyr Leu Gly Ser Leu Ala Phe Leu Gly Ala Asp Thr Ala Arg Leu Asp
177 -85          -80          -75          -70
179 gtg gcg gca gag ttc cga aag aaa tgg aat aag tgg gct cta agt cgt 270
180 Val Ala Ala Glu Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu Ser Arg
181          -65          -60          -55
183 gga aaa aga gaa ctt cgg ctg tcc agc agc tac ccc acc ggg atc gcc 318
184 Gly Lys Arg Glu Leu Arg Leu Ser Ser Tyr Pro Thr Gly Ile Ala
185          -50          -45          -40
187 gac ttg aag gcc ggg cct gcc cag act gtc att cgg ccc cag gat gtg 366
188 Asp Leu Lys Ala Gly Pro Ala Gln Thr Val Ile Arg Pro Gln Asp Val
189          -35          -30          -25
191 aag gcc tcc tct cgc agc ccc cag gcc agc att cgg gat gca gcc cgc 414
192 Lys Gly Ser Ser Arg Ser Pro Gln Ala Ser Ile Pro Asp Ala Ala Arg
193          -20          -15          -10
195 atc cga gtc aag cgc tac cgc cag agt atg aac aac ttc cag gcc ctg 462
196 Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn Asn Phe Gln Gly Leu
197 -5          -1 1          5          10
199 cgg agc ttc gcc tgt cgc ttt ggg acg tgc acc gtg cag aag ctg gcg 510
200 Arg Ser Phe Gly Cys Arg Phe Gly Thr Cys Thr Val Gln Lys Leu Ala
201          15          20          25
203 cac cag atc tac cag ttc acg gac aaa gac aag gac ggc gtc gcc ccc 558
204 His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Gly Val Ala Pro
205          30          35          40
207 cgg agc aag atc agc ccc cag gcc tac gcc cgc cgg cgc cga cgc tct 606
208 Arg Ser Lys Ile Ser Pro Gln Gly Tyr Gly Arg Arg Arg Arg Ser
209          45          50          55
211 ctg ccc gaa gcc agc ctg gcc cgg act ctg agg tcc cag gag cca cag 654

```

RAW SEQUENCE LISTING
 PATENT APPLICATION: US/10/018,924

DATE: 01/17/2002
 TIME: 07:15:17

Input Set : A:\SO042PCTSEQ.txt
 Output Set: N:\CRF3\01172002\J018924.raw

```

212 Leu Pro Glu Ala Ser Leu Gly Arg Thr Leu Arg Ser Gln Glu Pro Gln
213 60 65 70 75
215 ggc cac ggg gcc ccg gcc tcc ccg gcg cat caa gtg ctc gcc act ctc 702
216 Ala His Gly Ala Pro Ala Ser Pro Ala His Gln Val Leu Ala Thr Leu
217 80 85 90
219 ttt agg att taggcgccta ctgtggcagc agcgaaacagt cgcgcgatgca 751
220 Phe Arg Ile
222 tcatgccggc gcttccctggg gcggggggct tcccggagcc gagccccctca gcggctgggg 811
224 cccgggcaga gacagcattg agagaccgag agtccgggag gcacagacca gcggcgagcc 871
226 ctgcattttc aggaaccctg cctgcttgga gccagtgttc tcttcggctt aatccagccc 931
228 ggggtcccggt gtgggggtgg aggggtgcaga ggaatccaaa ggaagtgtcat ctgcaggct 991
230 caccggagagg agaaactgcg aagtaaattg ttagaccccc aggggcaagg gtctgagcca 1051
232 ctgcctgtgc gccacacaaac tgattttctga aggggaataa ccccaacagg gcgcaagcct 1111
234 cactattact tgaactttcc aaacacctaga gaggaaaagt gcaatgtatg ttgtatataa 1171
236 agaggtaact atcaattatt aagtttgttg ctgtcaagat tttttttgtg aacttcaaat 1231
238 atagagatat ttttgtacgt tatatatgtt attaagggca ttttaaaaca attgtattgt 1291
240 tccccotccc tctattttaa tatgtgaatg tctcagcgag gtgtaacatt gtttgcgtgc 1351
242 cgaatgtga gagtgtgtgt gtgtgtgtgc gtgaagaga gtctggatgc ctcttgggga 1411
244 agaagaaaac accatatctg tataatctat ttacataaaa tgggtgatat gcgaagtagc 1471
246 aaaccaataa actgtctctaa tg 1493
249 <210> SEQ ID NO: 4
250 <211> LENGTH: 188
251 <212> TYPE: PRT
252 <213> ORGANISM: Sus scrofa
254 <400> SEQUENCE: 4
255 Met Lys Leu Val Pro Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe
256 -90 -85 -80
258 Leu Gly Ala Asp Thr Ala Arg Leu Asp Val Ala Ala Glu Phe Arg Lys
259 -75 -70 -65
261 Lys Trp Asn Lys Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Leu
262 -60 -55 -50
264 Ser Ser Ser Tyr Pro Thr Gly Ile Ala Asp Leu Lys Ala Gly Pro Ala
265 -45 -40 -35
267 Gln Thr Val Ile Arg Pro Gln Asp Val Lys Gly Ser Ser Arg Ser Pro
268 -30 -25 -20 -15
270 Gln Ala Ser Ile Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg
271 -10 -5 -1 1
273 Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe
274 5 10 15
276 Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr
277 20 25 30
279 Asp Lys Asp Lys Asp Gly Val Ala Pro Arg Ser Lys Ile Ser Pro Gln
280 35 40 45 50
282 Gly Tyr Gly Arg Arg Arg Arg Ser Leu Pro Glu Ala Ser Leu Gly
283 55 60 65
285 Arg Thr Leu Arg Ser Gln Glu Pro Gln Ala His Gly Ala Pro Ala Ser
286 70 75 80
288 Pro Ala His Gln Val Leu Ala Thr Leu Phe Arg Ile
289 85 90

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/018,924

DATE: 01/17/2002

TIME: 07:15:17

Input Set : A:\SO042PCTSEQ.txt

Output Set : N:\CRF3\01172002\J018924.raw

```

292 <210> SEQ ID NO: 5
293 <211> LENGTH: 1376
294 <212> TYPE: DNA
295 <213> ORGANISM: Rattus norvegicus
297 <220> FEATURE:
298 <221> NAME/KEY: CDS
299 <222> LOCATION: (154)..(708)
301 <220> FEATURE:
W--> 302 <221> NAME/KEY: mat peptide
303 <222> LOCATION: (433)..(582)
305 <400> SEQUENCE: 5
306 tccagccttt accgctctg gtttctcggc ttctcctgcg agtcagtttt ggactttgcy 60
308 gggttttgccg ctgtcagaag gacgtctcgg acttttctgct tcaagtgttt gacaactcac 120
310 ccttttcgca ggggtatcgga gcctcgctac aga atg aag ctg gtt tcc atc gcc 174
311 Met Lys Leu Val Ser Ile Ala
312 -90
314 ctg atg tta ttg ggt tcg ctc gcc gtt ctc ggc gcg gac acc gca cgg 222
315 Leu Met Leu Leu Gly Ser Leu Ala Val Leu Gly Ala Asp Thr Ala Arg
316 -85 -80 -75
318 ctg gac act tcc tcg cag ttc cga aag aag tgg aat aag tgg gcg cta 270
319 Leu Asp Thr Ser Ser Gln Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu
320 -70 -65 -60 -55
322 agt cgt ggg aag agg gaa cta caa gcg tcc agc agc tac cct acg ggg 318
323 Ser Arg Gly Lys Arg Glu Leu Gln Ala Ser Ser Ser Tyr Pro Thr Gly
324 -50 -45 -40
326 ctg gtt gat gag aag aca gtc ccg acc cag act ctt ggg ctg cag gac 366
327 Leu Val Asp Glu Lys Thr Val Pro Thr Gln Thr Leu Gly Leu Gln Asp
328 -35 -30 -25
330 aag cag agc acg tct agc acc cca caa gcc agc act cag agc aca gcc 414
331 Lys Gln Ser Thr Ser Ser Thr Pro Gln Ala Ser Thr Gln Ser Thr Ala
332 -20 -15 -10
334 cac att cga gtc aaa cgc tac cgc cag agc atg aac cag ggg tcc cgc 462
335 His Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn Gln Gly Ser Arg
336 -5 -1 1 5 10
338 agc act gga tgc cgc ttt ggg acc tgc aca atg cag aaa ctg gct cac 510
339 Ser Thr Gly Cys Arg Phe Gly Thr Cys Thr Met Gln Lys Leu Ala His
340 15 20 25
342 cag atc tac cag ttt aca gac aaa gac aag gac ggc atg gcc ccc aga 558
343 Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Gly Met Ala Pro Arg
344 30 35 40
346 aac aag atc agc cct caa ggc tat ggc cgc cgg cgc cgt tcc ctg 606
347 Asn Lys Ile Ser Pro Gln Gly Tyr Gly Arg Arg Arg Arg Arg Ser Leu
348 45 50 55
350 cca gag gtc ctg cga gcc cgg act gtg gag tcc tcc cag gag cag aca 654
351 Pro Glu Val Leu Arg Ala Arg Thr Val Glu Ser Ser Gln Glu Gln Thr
352 60 65 70
354 cac tca gct cca gcc tcc ccg gcg cac caa gac atc tcc aga gtc tct 702
355 His Ser Ala Pro Ala Ser Pro Ala His Gln Asp Ile Ser Arg Val Ser
356 75 80 85 90

```

VERIFICATION SUMMARY

DATE: 01/17/2002

PATENT APPLICATION: US/10/018,924

TIME: 07:15:18

Input Set : A:\SO042PCTSEQ.txt

Output Set: N:\CRF3\01172002\J018924.raw

L:5 M:283 W: Missing Blank Line separator, <130> field identifier
L:7 M:270 C: Current Application Number differs, Replaced Application Number
L:8 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:26 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1
L:163 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:3
L:302 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5

DESCRIPTION

COMPOSITION FOR PROMOTING PASSIVE EXTENSION OF BLADDERSMOOTH MUSCLE

5

TECHNICAL FIELD

The present invention relates to a composition for promoting extension of smooth muscle of the urinary bladder, comprising adrenomedullin.

10

BACKGROUND ART

Urinary incontinence is a common but very severe condition which mostly causes patients to be embarrassed, encounter difficulties, and be driven to despair. Clearly, there is a strong demand for a reliable and safe method of treating urinary incontinence. To date such a demand has not been satisfied to an appropriate level.

15
20

Urinary incontinence refers to a condition in which urine involuntarily flows out during the storage phase, and which is caused when there is a functional or organic abnormality in one or both of the urinary bladder and the urethra. Urinary incontinence occurs when bladder smooth muscle is involuntarily contracted so that the internal pressure of the urinary bladder is increased, or when urethral closure pressure created by the urethral sphincter and a supporting tissue surrounding the urethra is too weak to repel the internal pressure of the normal urinary bladder. Urinary incontinence is divided into several types depending on the pathology. Broad types are: urge incontinence; reflex incontinence; overflow incontinence

25
30

(poorly compliant bladder), stress incontinence, total incontinence; and nocturnal enuresis.

Urge incontinence is a condition in which urine
5 involuntarily flows out accompanying a strong urge to urinate, or after feeling an urge to urinate, a patient cannot resist urine outflow and wets before reaching a toilet. These are divided into motor and sensory types. Motor urge
10 incontinence is caused by a disorder of an inhibitory pathway for the micturition reflex, or excitation of an excitatory pathway, a representative example of which is neurogenic bladder due to a lesion, such as for example a cerebrovascular disorder and a brain tumor. Representative
15 examples of sensory urge incontinence include cystitis and urethritis.

Reflex incontinence is a condition in which when the urinary bladder is filled with urine to some extent without
a normal urge to urinate, the urinary bladder is reflectively
20 contracted, so that urine involuntarily flows out. Reflex incontinence includes neurogenic bladder due to injury of the spinal cord above the urination center in the sacral spinal cord, urinary incontinence of infants, and the like.

25 Overflow incontinence is a condition in which since urine cannot be sufficiently excreted, the urinary bladder is excessively filled with urine and the urine gradually flows out. Overflow incontinence includes neurogenic
30 bladder (poorly compliant bladder) due to injury of peripheral nerves, and disorders of the passage of the lower urinary tract due to prostatic hypertrophy or cancer.

Stress incontinence is a symptom in which when a

patient strains in sneezing or coughing, laughs, runs, or the like, so that abdominal pressure is rapidly increased, urine flows out without contraction of the urinary bladder. The increase in the abdominal pressure leads to a raise in the internal pressure of the urinary bladder. In this case, if the increased internal pressure exceeds the urethral closure pressure, urine flows out. Females more often suffer from this disorder. A major cause of stress incontinence is that supporting tissues surrounding the urethra are seriously weakened by parturition or aging, so that urethral closure pressure cannot be sufficiently generated.

Total incontinence is a condition characterized by dysfunction of the urethral sphincter, and in which urine flows out from the urethra at all times irrespective of the presence or absence of abdominal pressure. The cause of total incontinence is injury of the urethral sphincter caused by trauma of the pelvis or surgery of the prostate.

Nocturnal enuresis is also called bed-wetting, which is a condition in which patients of 4 or more years old, which is the age at which the habit of urinating is established, unconsciously void urine during sleep though they do not have an organic abnormality in the urinary tract or the nerve system and can urinate normally (no urinary incontinence) on awakening. This disorder is caused by the premature inhibitory mechanism of the central nerve system for the micturition reflex.

At present, anticholinergic agents are generally used for treatment of the following patients having urine storage disorders: (1) neurogenic bladder patients who have

urinary incontinence due to the hyperactivity of urinary bladder and involuntarily urinate; (2) neurogenic bladder patients who do not have abnormal urinary bladder contraction but have a poorly compliant urinary bladder in which the internal pressure of the urinary bladder gradually increased as urine is filled; (3) one subset of patients who chiefly complain of pollakiuria; etc. Clinically, despite the efficacy of anticholinergic agents against urine storage disorders, when the anticholinergic agents are actually used, urinary bladder contraction is inhibited in urination so that urination disorders are often exacerbated to cause side effects, such as increased residual urine and anuresis.

As described above, clearly, urinary incontinence is one of today's major diseases, but current therapeutic methods are not satisfactory. There is a demand for a novel drug for treating urinary incontinence. The term "urination disorder" as used herein refers to an abnormal urination condition, such as urinary incontinence, caused by insufficient extension of bladder smooth muscle. Examples of urination disorders include urinary incontinence (e.g., urge incontinence), frequent urination, nocturnal pollakiuria. An agent capable of promoting extension of bladder smooth muscle would be expected to help bladder smooth muscle extend during storage phase to reduce the internal pressure of the urinary bladder. Thus, such an agent would be considered to be useful as drugs for treatment of urinary incontinence and other symptoms relating to urination.

It has been known that adrenomedullin has a vasodilatory action. For example, Nakamura et al., Jpn. J.

Pharmacol. 67, 259-262 (1995) has reported in Figure 1 that contracted mesenteric artery is extended by addition of adrenomedullin in a concentration-dependent manner. However, vasodilation cannot be considered to be identical with passive extension of muscle of the urinary bladder. For example, Nishimura et al., British J. Pharmacology, 120, 193-200 (1997) describes in Figure 6 that addition of adrenomedullin to the urinary bladder does not cause contraction or extension (active extension) of the urinary bladder.

The present invention is intended to solve the above-described problems. The objective of the present invention is to provide a novel agent for promoting passive extension of bladder smooth muscle.

DISCLOSURE OF THE INVENTION

The inventions found that adrenomedullin originally identified as a peptide having a hypotensive action does not directly extend bladder smooth muscle, but has an action of promoting passive extension of the urinary bladder wall due to urine storage (i.e., an action of promoting extension of bladder smooth muscle) and based on that finding, completed the present invention.

Adrenomedullin does not inhibit contraction of the urinary bladder due to acetylcholine (i.e., urinary bladder contraction in urination) and therefore, can provide a therapeutic agent for ameliorating a urine storage disorder without inhibiting urinary bladder contraction in urination and substantially without side effects.

A composition of the present invention for promoting passive extension of bladder smooth muscle comprises adrenomedullin. The composition may be used to ameliorate a urination disorder. The urination disorder may be a urinary incontinence selected from the group consisting of urge incontinence, reflex incontinence, and overflow incontinence.

In one embodiment, the adrenomedullin may be any of the following peptides: (a) a peptide comprising an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; (b) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle; (c) a peptide comprising an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; (d) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (c), and having an action of promoting extension of bladder smooth muscle; (e) a peptide comprising an amino acid sequence from Ala in position -73 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; (f) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (e), and having an action of promoting extension of bladder smooth muscle; (g) a peptide comprising an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ ID NO: 2 in SEQUENCE LISTING; and (h) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (g), and having an action of promoting extension

of bladder smooth muscle.

In another embodiment, the C-terminus of the adrenomedullin may be amidated. Gly may be added to the C-terminus of the adrenomedullin.

In another embodiment, in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING may be crosslinked. The crosslink may be a disulfide bond or a $-CH_2-CH_2-$ bond.

A method of the present invention for ameliorating a urination disorder uses a composition comprising adrenomedullin.

The present invention also provides use of adrenomedullin in production of a drug for ameliorating a urination disorder.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic diagram showing a method for dissecting the urinary bladder. As shown in Figure 1(a), ends of the urinary bladder were cut off along solid lines, and the urinary bladder was cut open along dashed lines. Four urinary bladder sections were obtained from the cut-open urinary bladder along three solid lines as shown in Figure 1(b).

Figure 2 is a graph showing the results of measurement of the effect of adrenomedullin on extension of the urinary bladder where the applied tension is 1 g. White circles indicate controls, while black circles

indicate the case of addition of adrenomedullin.

Figure 3 is a graph showing the results of measurement of the effect of adrenomedullin on contraction
5 of the urinary bladder due to acetylcholine.

Figure 4 is a diagram showing the amino acid sequence of adrenomedullin derived from human pheochromocytoma. RE1 to RE6 indicate fragments produced
10 by digesting the amino acid sequence with arginylendopeptidase.

BEST MODE FOR CARRYING OUT THE INVENTION

15 When carrying out the present invention, protein separation and analysis methods, recombinant DNA techniques, and assays, which are known in the art, may be employed unless otherwise specified.

20 I. Definition

Hereinafter, the terms used herein to explain the present invention will be described.

An "adrenomedullin" is a peptide having a
25 hypotensive action, originally isolated from human pheochromocytoma. The term "adrenomedullin" as used herein is not limited to the particular peptide, but includes peptides having substantial homology in the amino acid sequence with that peptide. Examples of the homologous
30 peptides include species mutants and allelic mutants. Human-derived adrenomedullin comprises an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING. (The peptide consisting

of an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ ID NO: 2 in SEQUENCE LISTING is believed to be preproadrenomedullin. The peptide obtained by processing of a signal peptide and consisting of an amino acid sequence from Ala in position -73 to Leu in position 91 of SEQ ID NO: 2 in SEQUENCE LISTING is believed to be proadrenomedullin. The peptide consists of an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING is an adrenomedullin fragment which has been confirmed to have a hypotensive action. Adrenomedullin in any of the above-described forms may be employed in the present invention.) Human-derived adrenomedullin may be encoded by a polynucleotide sequence from T in position 447 to C in position 602 of SEQ ID NO: 1 in SEQUENCE LISTING.

Porcine-derived adrenomedullin comprises an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 4 in SEQUENCE LISTING. Porcine-derived adrenomedullin may be encoded by a polynucleotide sequence from T in position 430 to C in position 585 of SEQ ID NO: 3 in SEQUENCE LISTING. Rat-derived adrenomedullin comprises an amino acid sequence from Tyr in position 1 to Tyr in position 50 of SEQ ID NO: 6 in SEQUENCE LISTING. Rat-derived adrenomedullin may be encoded by a polynucleotide sequence from T in position 433 to T in position 582 of SEQ ID NO: 5 in SEQUENCE LISTING.

Clearly, human-derived peptides are preferable for human diseases or treatment of a human. However, homologous peptides derived from other mammals may also be employed for some purposes. Further, comparison of human-derived peptides with peptides derived from other mammals is

important when an attempt is made to obtain a variant maintaining a desired activity of a human-derived peptide.

Adrenomedullin used in the present invention is not necessarily limited to the above-described sequences, but includes, as subjects, homologous peptides having an amino acid sequence which has one or several amino acid deleted, substituted, or added in the above-described sequences and maintaining a desired activity.

10

Amino acid conservative substitution is one preferable means for obtaining homologous peptides. Conservative substitution representatively includes substitutions conducted within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine.

The homology between two amino acid sequences is determined by optionally introducing a gap to optimize residue matching. A peptide having an amino acid sequence, which has substantially homology with the amino acid sequence of human adrenomedullin, has representatively about 60% homology with the amino acid sequence of human adrenomedullin, preferably at least about 70%, more preferably at least about 80%, and in an especially preferable embodiment, at least about 90% or more. Software for determining homology is easily available.

In the present invention, a peptide is by definition referred to "have an action of promoting extension of bladder smooth muscle" if the degree of extension of the urinary bladder is about 80% or more and preferably about 90% or

more of the value indicated in the experimental sample of Example 1 described below when measured under substantially the same conditions as those of Example 1 below.

5 The C-terminus of a peptide used in the present invention may or may not be amidated. "Amidation of C-terminus" refers to one of modification reactions of a peptide, in which the COOH group of the C-terminal amino acid of a peptide is changed to the form of CONH_2 . A number of biologically active peptides functioning in vivo are first biosynthesized as a precursor protein having a larger molecular weight. The precursor protein is then matured by a modification reaction such as for example the amidation of the C-terminus. The amidation is conducted by a C-terminal amidating enzyme acting on the precursor protein. The precursor protein always includes a Gly residue on the C-terminal side of a residue to be amidated, which is frequently followed by a basic amino acid sequence pair, such as for example Lys-Arg or Arg-Arg, on the C-terminal side (Mizuno, Seikagaku, Vol. 61, No. 12, pp. 1435-1461 (1989)).

II. Adrenomedullin having an action of promoting extension of bladder smooth muscle

25 In the present invention, adrenomedullin is utilized as an effective component of a composition for promoting extension of bladder smooth muscle. Adrenomedullin is utilized as an effective component for manufacturing a drug for ameliorating a urination disorder.

30 Adrenomedullin may be isolated from naturally-occurring sources, produced using recombinant DNA techniques, or chemically synthesized.

When adrenomedullin is isolated from naturally-occurring sources, purification may be conducted, for example, in the following way. For example, firstly human pheochromocytoma is pulverized to obtain a crude extract
5 which is in turn subjected to various chromatography techniques for purification. In this case, by monitoring an increase in the cAMP activity of platelets, a fraction containing adrenomedullin of interest can be obtained. Method for isolation and purification of adrenomedullin are
10 described in Japanese Laid-Open Publication No. 7-196693.

When adrenomedullin is produced using recombinant DNA techniques, the DNA sequence encoding a peptide of interest is expressed using various recombinant systems.
15 Construction of expression vectors and preparation of transformants having appropriate DNA sequences are conducted by methods known in the art. Expression may be conducted using prokaryote systems or eukaryote systems.

Prokaryote hosts used include E.coli, bacillus, and other bacteria. For such prokaryote hosts, plasmid vectors having replication sites and control sequences compatible with the hosts are used. For example, E.coli is typically transformed with a derivative of pBR322 which is a plasmid
25 derived from E.coli. The control sequence herein is defined to include a promoter for initiation of transcription, an operator if necessary, and a ribosome binding site. Such a control sequence includes generally used promoters such as for example β -lactamase and lactose promoter systems (Chang et al., Nature (1977) 198, 1056), tryptophan
30 promoters (Goeddel et al., Nucleic Acids Res., (1980) 8: 4057), and P_L promoters derived from λ and N-gene ribosome binding sites (Shimatake, Nature (1981) 292, 128).

As a eukaryote host, yeast is used, for example. For such a host eukaryote, a plasmid vector having a replication site and a control sequence compatible with the host is used. For example, yeast is transformed with pYEura3 (Clontech). Other promoters useful in a yeast host include, for example, promoter classes for synthesizing a glycolytic enzyme, such as for example a promoter for 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem. (1980) 255, 2073). Other promoters include those derived from an enolase gene or those derived from a Leu2 gene obtained from YEp13.

Appropriate mammalian promoters include metallothionein, an early or late promoter derived from SV40, and other virus promoters such as for example those derived from polyoma virus, adenovirus II, bovine papilloma virus and avian sarcoma virus.

A transformant can be obtained by introducing an expression vector into an appropriate host cell. A desired adrenomedullin can be obtained by culturing the transformant under appropriate conditions.

Chemical synthesis of adrenomedullin may be conducted within a method known in the art. For example, adrenomedullin may be synthesized by a solid phase method using a peptide synthesizer. A C-terminal amidated peptide can be synthesized on a peptide synthesizer by condensing amino acids sequentially from the C-terminal amino acid to the N-terminal amino acid using a benzhydryl amine resin and a standard DCC/HOBt, and cutting out an intended peptide from the resultant peptide resin by a standard cleavage

method (trifluoromethanesulfonic acid method).

A C-terminal amidated adrenomedullin may be obtained by one of the following: a carboxyl group at the C-terminus of the peptide obtained by expression in a host is chemically amidated; or a peptide is prepared so as to have Gly added to the C-terminus of an intended amino acid sequence, and is then allowed to react with the above-mentioned C-terminal amidating enzyme for amidation.

Alternatively, the peptide obtained by adding Gly to the C-terminus of adrenomedullin may be amidated due to an action of a C-terminal amidating enzyme in vivo as described above.

A disulfide bond can be formed, for example, by oxidizing a peptide by air oxidation or with an appropriate oxidant. The substitution of the disulfide bond can be conducted with a $-CH_2-CH_2-$ bond by a well-known method (O. Keller et al., *Helv. Chim. Acta* (1974) 57: 1253). Generally, cleavage in the disulfide bond is avoided by substituting a $-CH_2-CH_2-$ bond for the disulfide bond, resulting in stabilization of the protein.

Assay methods for action of promoting extension of bladder smooth muscle, which are known in the art, may be used to confirm that the thus-obtained adrenomedullin has an action of promoting extension of bladder smooth muscle. Examples of such assays include a method employing the urinary bladder isolated from any animal, and a method of measuring the internal pressure of the urinary bladder under anesthetization. When the urinary bladder isolated from a rat is used, for example, action of promoting extension of

bladder smooth muscle may be assayed under the following conditions. The urinary bladder is isolated from a rat and cut into several pieces to obtain urinary bladder strips. While the resultant urinary bladder strips are immersed in a buffer solution, such as for example Tyrode's solution, extension or contraction of the urinary bladder is continuously examined using a measuring apparatus, such as for example an isometric transducer and an isotonic transducer. The urinary bladder is allowed to be extended in the presence or absence of a subject peptide, and extension of the urinary bladder is compared between the two cases to judge whether or not the peptide has an action of promoting extension of bladder smooth muscle.

III. Preparation of a composition for promoting extension of bladder smooth muscle

A composition of the present invention comprises an effective amount of adrenomedullin and may further comprise any excipient known to those skilled in the art. Examples of the excipients include lactose, cornstarch, magnesium stearate, and alum.

The composition of the present invention is prepared in accordance with methods known in the art.

The composition of the present invention may be in any form. The composition of the present invention may be a solid, such as for example a tablet, a pill, a capsule, and a granule; or a liquid, such as for example an aqueous solution and a suspension. When the composition of the present invention is orally administered as a tablet, an excipient, such as for example lactose, cornstarch, and magnesium stearate, may be commonly used. When the

composition of the present invention is orally administered as a capsule, an excipient, such as for example lactose and dried cornstarch, may be commonly used. In order to orally administer adrenomedullin as an aqueous suspension, the adrenomedullin may be used in combination with an emulsion or a suspension. The aqueous suspension may optionally contain a sweetener and an aroma chemical. When the composition of the present invention is intramuscularly, intraperitoneally, subcutaneously, or intravenously injected, adrenomedullin is dissolved in a sterilized solution to prepare a buffer solution which is in turn adjusted into an appropriate pH. When the composition of the present invention is intravenously administered, the composition is preferably isotonic.

The composition of the present invention may be used as a drug for ameliorating a urination disorder.

IV. Administration of a composition for promoting extension of bladder smooth muscle

The composition of the present invention may be administered in the form of a conventional peptide formulation as described in Remington's Pharmaceutical Sciences, Mack Publishing, Easton, PA. For example, the composition of the present invention may be administered orally, or alternatively parenterally, such as for example intravenous administration, intramuscular injection, intraperitoneal injection, and subcutaneous injection. The peptide may be administered by injection into the urinary bladder.

When the composition of the present invention is administered into a human subject, typically, the dose per

day can be appropriately determined by those skilled in the art by taking into consideration a patient's symptoms, severity, individual differences in sensitivity, weight, age, and the like. The composition of the present invention
5 may be administered once a day or several times a day.

Urination disorders would be ameliorated by administration of the composition of the present invention.

10 (Examples)

Hereinafter, the action of adrenomedullin of the present invention as a drug for promoting extension of bladder smooth muscle will be more specifically described. The present invention is not limited to the following
15 examples. Adrenomedullin used in the examples is a synthesized peptide consisting of an amino acid sequence from Tyr in position 1 to Tyr in position 50 of SEQ ID NO: 6 (available from Peptide Institute, Inc.).

20 (Example 1: Effect of adrenomedullin on extension of the urinary bladder of a male rat)

8 to 16 weeks old male rats were sacrificed by hammering their heads. Thereafter, the rats were decapitated, followed by exsanguination. The urinary
25 bladders were isolated from the rats. Each isolated urinary bladder was cut into four portions, thereby obtaining urinary bladder strips (Figure 1).

The effect of adrenomedullin on the rat urinary
30 bladder was examined by measuring contractions of the urinary bladder strips using an isotonic transducer TD-112S (manufactured Nippon Kohden Corporation) where the tension was 1 g.

The urinary bladder strips were firstly immersed in 30 ml of Tyrode's solution with 100 nM adrenomedullin (experimental sample) or without it (control sample). In this situation, the sections were attached to the isometric transducer where the tension was 1 g, to continuously measure relaxation of the urinary bladder. The composition of the Tyrode's solution is as follows: 139 mM NaCl, 2.7 mM KCl, 11.9 mM NaHCO₃, 2.6 mM MgCl₂·6H₂O, 0.4 mM NaH₂PO₄·2H₂O, 1.7 mM CaCl₂, and 5.5 mM glucose; pH 7.4).

The above-described experiment was repeated five times. The results are shown in Figure 2. Solid colored circles indicate the results of the experimental sample, while plain circles indicate averages of the control sample. Vertical bars indicate the standard deviation of a two-way analysis of variance. The vertical axis indicates the length of relaxation (mm), while the horizontal axis indicate time (minutes).

As shown in Figure 2, when tension was applied to the urinary bladder in the presence of adrenomedullin to cause the urinary bladder to be extended, the result obtained is that the urinary bladder wall was more extended compared to the case of the absence of adrenomedullin. Normally, the urinary bladder is passively extended by urine filling therein during the urine storage phase, and the extension prevents the internal pressure of the urinary bladder from being increased, so that the internal pressure of the urinary bladder remains at a constant low value. A high expansibility of the urinary bladder is referred to as a high level of compliance. As a result of this example, it was demonstrated that adrenomedullin causes the urinary

bladder to remain in a higher compliance state during the urine storage phase, thereby increasing the capacity of the urinary bladder.

5 (Example 2: Effect of adrenomedullin on static tension, and contraction due to acetylcholine of the urinary bladder of a male rat)

Urinary bladder strips were prepared in a manner similar to that of Example 1. The urinary bladder sections
10 were attached to an isometric transducer FD pickup TB611T (manufactured by Nippon Kohden Corporation) in Tyrode's solution. Contraction of the urinary bladder was continuously measured. Firstly, 30 nM to 1 mM acetylcholine was added to the Tyrode's solution. As a
15 result, contraction of the urinary bladder occurred (Figure 3). In Figure 3, the vertical axis indicates tension (unit: g), while the horizontal axis indicates time. Contraction induced by acetylcholine was confirmed, followed by washing out acetylcholine. Thereafter, 100 nM
20 adrenomedullin was added to the Tyrode's solution. As a result, the urinary bladder was not contracted. Further, 30 nM to 1 mM acetylcholine was added to the Tyrode's solution. As a result, recontraction of the urinary bladder occurred. The contraction induced by acetylcholine alone
25 before the addition of adrenomedullin was not significantly different from the contraction induced by acetylcholine in the presence of adrenomedullin.

Therefore, the tested adrenomedullin did not affect
30 the static tension of the urinary bladder, or exhibit an effect of preventing contraction of the urinary bladder due to acetylcholine, which is believed to correspond to contraction of the urinary bladder during a voiding phase.

INDUSTRIAL APPLICABILITY

5 According to the present invention, a composition for promoting extension of bladder smooth muscle, comprising adrenomedullin is provided. Such a composition is useful for ameliorating a urination disorder selected from the group consisting of urge incontinence, reflex incontinence, and overflow incontinence.

CLAIMS

1. A composition for promoting passive extension of bladder smooth muscle, comprising adrenomedullin.
2. A composition according to claim 1, used to ameliorate a urination disorder.
3. A composition according to claim 2, wherein the urination disorder is a urinary incontinence selected from the group consisting of urge incontinence, reflex incontinence, and overflow incontinence.
4. A composition according to claim 1, wherein the adrenomedullin is:
 - (a) a peptide comprising an amino acid sequence from Ser in position 13 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or
 - (b) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (a), and having an action of promoting extension of bladder smooth muscle.
5. A composition according to claim 4, wherein the adrenomedullin is:
 - (c) a peptide comprising an amino acid sequence from Tyr in position 1 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or
 - (d) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (c), and having an action of promoting extension of bladder smooth muscle.

6. A composition according to claim 5, wherein the adrenomedullin is:

(e) a peptide comprising an amino acid sequence from Ala in position -73 to Tyr in position 52 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(f) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (e), and having an action of promoting extension of bladder smooth muscle.

7. A composition according to claim 6, wherein the adrenomedullin is:

(g) a peptide comprising an amino acid sequence from Met in position -94 to Leu in position 91 of SEQ ID NO: 2 in SEQUENCE LISTING; or

(h) a peptide comprising an amino acid sequence having one or several amino acid deleted, substituted, or added in the amino acid sequence (g), and having an action of promoting extension of bladder smooth muscle.

8. A composition according to any of claims 1 and 4 to 7, wherein the C-terminus of the adrenomedullin is amidated.

9. A composition according to any of claims 1 and 4 to 7, wherein Gly is added to the C-terminus of the adrenomedullin.

10. A composition according to any of claims 1 and 4 to 7, wherein in the adrenomedullin, Cys in position 16 and Cys in position 21 of SEQ ID NO: 2 in SEQUENCE LISTING are crosslinked.

11. A composition according to claim 10, wherein the crosslink is a disulfide bond.

12. A composition according to claim 10, wherein the crosslink is a $-\text{CH}_2-\text{CH}_2-$ bond.
- 5 13. A method for ameliorating a urination disorder using a composition comprising adrenomedullin.
14. Use of adrenomedullin in production of a drug for ameliorating a urination disorder.

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216

1/3

FIG. 1





FIG. 2




2/3

* Contraction induced by addition of acetylcholine is not significantly influenced by the presence of adrenomedullin.

FIG. 3


Contraction induced by acetylcholine
 (0.01M ~ 1mM) ↓

Contraction induced by acetylcholine
 of 100 nM adrenomedullin
 (0.01M ~ 1mM) ↓



Static tension is not changed by adrenomedullin alone.

FIG. 4



SEQUENCE LISTING

<110> Shionogi & Co., Ltd

<120> Composition for promoting passive extension of bladder smooth muscle

<130> S0042PCT

<140>

<141>

<150> JP P1999-177549

<151> 1999-06-23

<160> 6

<170> PatentIn Ver. 2.0

<210> 1

<211> 1457

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (165)..(719)

<220>

<221> mat peptide

<222> (447)..(602)

<400> 1

ggcagcagct ggatagaaca gcicaagcct igccacttcg ggctcttcac tgcagctggg 60

cttggcattc ggagttttgc catigccagt gggacgtctg agactttctc cttaagtaac 120

ttagcagaic acttccttag cagggctctg gcttcgcagc cggg atg aag cig gtt 176

Met Lys Leu Val

tcc gtc gcc ctg atg tac ctg ggt tgc ctc gcc ttc cta ggc gct gac 224
 Ser Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe Leu Gly Ala Asp
 -90 -85 -80 -75

acc gct cgg ttc gat gtc cgc tgc gag ttt cga aag aag tgg aat aag 272
 Thr Ala Arg Leu Asp Val Ala Ser Glu Phe Arg Lys Lys Trp Asn Lys
 -70 -65 -60

tgg gct ctg agt cgt ggg aag agg gaa ctg cgg atg tcc agc agc tac 320
 Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Met Ser Ser Ser Tyr
 -55 -50 -45

ccc acc ggg ctc gct gac gtg aag gcc ggg cct gcc cag acc ctt att 368
 Pro Thr Gly Leu Ala Asp Val Lys Ala Gly Pro Ala Gln Thr Leu Ile
 -40 -35 -30

cgg ccc cag gac atg aag ggt gcc tct cga agc ccc gaa gac agc agt 416
 Arg Pro Gln Asp Met Lys Gly Ala Ser Arg Ser Pro Glu Asp Ser Ser
 -25 -20 -15

ccg gat gcc gcc cgc atc cga gtc aag cgc tac cgc cag agc atg aac 464
 Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn
 -10 -5 -1 1 5

aac ttc cag ggc ctc cgg agc ttt ggc tgc cgc ttc ggg acg tgc acg 512
 Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe Gly Thr Cys Thr
 10 15 20

gtg cag aag ctg gca cac cag atc tac cag ttc aca gat aag gac aag 560
 Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys
 25 30 35

gac aac gtc gcc ccc agg agc aag atc agc ccc cag ggc tac ggc cgc 608
 Asp Asn Val Ala Pro Arg Ser Lys Ile Ser Pro Gln Gly Tyr Gly Arg
 40 45 50

cgg cgc egg cgc tcc ctg ccc gag gcc ggc cgg ggt cgg act ctg gtg 656
 Arg Arg Arg Arg Ser Leu Pro Glu Ala Gly Pro Gly Arg Thr Leu Val
 55 60 65 70

tct tct aag cca caa gca cac ggg gct cca gcc ccc ccg agt gga agt 704
 Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro Pro Ser Gly Ser
 75 80 85

gct ccc cac ttt cit taggatttag gcgccatgg tacaaggaa agtcgcgcaa 759
 Ala Pro His Phe Leu
 90

gcatccccgt ggtagccccc gggacgaagg acttcccag cgggtgsggg accgggctct 819
 gacagccctg cggagaccct gagtccggga ggcaccgtcc ggcggcgagc tciggtttg 879
 caaggsgccc tcttctggg ggtcttcgt ctttagcctt gctcaggtgc aagtgcacca 939
 gggggcgggg tgcagaagaa tccgaggtt tgcaggctt aaggagagga gaaactgaga 999
 aatgaatgct gagaccccc gagcaggggt ctgagccaca gccgtgtcgc cccacaaact 1059
 gatitctac ggcgtgtcac cccaccagg cgcaagccic actattactt gaactttcca 1119
 aaacctaaag aggaaaagt caatgcgtgt tglacatata gagglaacta tcaatatita 1179
 agtttgtgc tgcagaatt tttttgttaa ctcaaatat agagataatt tigtactta 1239
 tatattgat taagggcatt ttaaaagcaa ttatatgtc ctcccctatt ttaagacgtg 1299
 aatgtctcag cgagggttaa agttgttcgc cgcgtggaat gtgagtgtgt ttgtgtgat 1359
 gaagagaaaa gactgattac ctctgtgtg gaagaaggaa acaccgagtc tctgtataat 1419
 ctatttacct aaaatgggtg atatgcgaac agcaaac 1457

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

Arg Thr Leu Val Ser Ser Lys Pro Gln Ala His Gly Ala Pro Ala Pro
 70 75 80

Pro Ser Gly Ser Ala Pro His Phe Leu
 85 90

<210> 3
 <211> 1493
 <212> DNA
 <213> Sus scrofa

<220>
 <221> CDS
 <222> (148)..(711)

<220>
 <221> mat peptide
 <222> (430)..(585)

<400> 3
 gcggacacgc tgcagcccttg ccacctctag ttctttacca cagcttggac gtcgggggttt 60

tgccactgcc agaggggacgt ctacagacttc atcttcccaa atcttggcag atcacccctt 120

tagcagggtc tgcacatctc agccggg atg aag ctg gtt ccc gta gcc ctc atg 174
 Met Lys Leu Val Pro Val Ala Leu Met

-90

tac ctg ggc tgc ctc gcc ttc ctg ggc gct gac aca gct cgg ctc gac 222
 Tyr Leu Gly Ser Leu Ala Phe Leu Gly Ala Asp Thr Ala Arg Leu Asp
 -85 -80 -75 -70

gtg gcg gca gag ttc cga aag aaa tgg aat aag tgg gct cta agt cgt 270
 Val Ala Ala Glu Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu Ser Arg

-65

-60

-55

gga aaa aga gaa ctt cgg ctg tcc agc agc tac ccc acc ggg atc gcc 318

Gly Lys Arg Glu Leu Arg Leu Ser Ser Ser Tyr Pro Thr Gly Ile Ala

-50

-45

-40

gac tlg aag gcc ggg cct gcc cag act gtc att cgg ccc cag gat gtg 366

Asp Leu Lys Ala Gly Pro Ala Gln Thr Val Ile Arg Pro Gln Asp Val

-35

-30

-25

aag ggc tcc tct cgc agc ccc cag gcc agc att ccg gat gca gcc cgc 414

Lys Gly Ser Ser Arg Ser Pro Gln Ala Ser Ile Pro Asp Ala Ala Arg

-20

-15

-10

atc cga gtc aag cgc tac cgc cag agt atg aac aac ttc cag ggc ctg 462

Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn Asn Phe Gln Gly Leu

-5

-1 1

5

10

cgg agc ttc ggc tgt cgc ttt ggg acg tgc acc gtc cag aag ctg gcg 510

Arg Ser Phe Gly Cys Arg Phe Gly Thr Cys Thr Val Gln Lys Leu Ala

15

20

25

cac cag atc tac cag ttc acg gac aaa gac aag gac ggc gtc gcc ccc 558

His Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Gly Val Ala Pro

30

35

40

cgg agc aag atc agc ccc cag ggc tac ggc cgc cgg cgc cga cgc tct 606

Arg Ser Lys Ile Ser Pro Gln Gly Tyr Gly Arg Arg Arg Arg Ser

45

50

55

ctg ccc gaa gcc agc ctg ggc cgg act ctg agg tcc cag gag cca cag 654

Leu Pro Glu Ala Ser Leu Gly Arg Thr Leu Arg Ser Gln Glu Pro Gln

60

65

70

75

gcg cac ggg gcc ccg gcc tcc ccg gcg cat caa gig ctc gcc act ctc 702

Ala His Gly Ala Pro Ala Ser Pro Ala His Gln Val Leu Ala Thr Leu

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

ttt agg att taggcgccia cigtggcagc agcgaacagt cgcgcaigca 751

Phe Arg Ile

tcaigccggc gcttccctggg gcggggggcct tcccggagcc gagccccica gcggctgggg 811

ccggggcaga gacagcattg agagaccgag agtccgggag gcacagacca gcggcgagcc 871

cigcattttc aggaaccgtt ccigtctgga ggcagtgttc tcttcggctt aatccagccc 931

gggtccccgg gtgggggtgg agggcgcaga ggaatccaaa ggagtgatc ctcagagct 991

cacggagagg agaaactgcg aagtaaatgc ttagaccccc aggggcaagg gtcigagcca 1051

cigccgtgcc gccacaaaac tgatttciga aggggaataa cccaacagg gcgcaagcct 1111

cactattact tgaactttcc aaaacctaga gaggaagaat gcaatgtatg ttgtatataa 1171

agaggtaact alcaatattt aagttgttg cgtcaaga tttttttgt aacticaaat 1231

atagagatat tttgtacgt tataattgt attaaggcca ttttaaaaca atgtattgt 1291

tcccccccc tctattttaa tatgtgaatg tctcagcgag gtgtaacatt gttgtctgcg 1351

cgaaatgta gagtggtgt gtgtgtgtgc gtgaaagaga gtciggaatc cctttggga 1411

agaagaaaac accatatctg tataatctat ttacataaaa igggtagat gcgaagtagc 1471

aaaccaataa actgtctcaa tg 1493

<210> 4

<211> 188

<212> PRT

<213> Sus scrofa

<400> 4

Met Lys Leu Val Pro Val Ala Leu Met Tyr Leu Gly Ser Leu Ala Phe
-90 -85 -80

Leu Gly Ala Asp Thr Ala Arg Leu Asp Val Ala Ala Glu Phe Arg Lys
-75 -70 -65

Lys Trp Asn Lys Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Arg Leu
-60 -55 -50

Ser Ser Ser Tyr Pro Thr Gly Ile Ala Asp Leu Lys Ala Gly Pro Ala
-45 -40 -35

Gln Thr Val Ile Arg Pro Gln Asp Val Lys Gly Ser Ser Arg Ser Pro
-30 -25 -20 -15

Gln Ala Ser Ile Pro Asp Ala Ala Arg Ile Arg Val Lys Arg Tyr Arg
-10 -5 -1 1

Gln Ser Met Asn Asn Phe Gln Gly Leu Arg Ser Phe Gly Cys Arg Phe
5 10 15

Gly Thr Cys Thr Val Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr
20 25 30

Asp Lys Asp Lys Asp Gly Val Ala Pro Arg Ser Lys Ile Ser Pro Gln
35 40 45 50

Gly Tyr Gly Arg Arg Arg Arg Ser Leu Pro Glu Ala Ser Leu Gly
55 60 65

Arg Thr Leu Arg Ser Gln Glu Pro Gln Ala His Gly Ala Pro Ala Ser
70 75 80

Pro Ala His Gln Val Leu Ala Thr Leu Phe Arg Ile

<210> 5
 <211> 1376
 <212> DNA
 <213> *Rattus norvegicus*

<220>
 <221> CDS
 <222> (154)..(708)

<220>
 <221> mat peptide
 <222> (433)..(582)

<400> 5
 tccagccitt accgctccig gtttctcggc ttctcaccgc agtcagtcitt ggactttgcg 60
 ggitttgccg cgtcagaag gacgctcgg acttctcgt tcaagtgctt gacaactcac 120
 ccttcagca gggtatcgga gcatcgtac aga atg aag ctg gtt tcc atc gcc 174
 Met Lys Leu Val Ser Ile Ala

-90

cig atg tta ttg ggt tgc ctc gcc gtt ctc ggc gcg gac acc gca cgg 222
 Leu Met Leu Leu Gly Ser Gln Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu
 -85 -80 -75

ctc gac act tcc tgc cag ttc cga aag aag tgg aat aag tgg gcg cta 270
 Leu Asp Thr Ser Ser Gln Phe Arg Lys Lys Trp Asn Lys Trp Ala Leu
 -70 -65 -60 -55

agt cgt ggg aag agg gaa cta caa gcg tcc agc agc tac cct acg ggg 318
 Ser Arg Gly Lys Arg Glu Leu Gln Ala Ser Ser Ser Tyr Pro Thr Gly
 -50 -45 -40

ctc gtt gat gag aag aca gtc ccg acc cag act ctt ggg ctc cag gac 366
Leu Val Asp Glu Lys Thr Val Pro Thr Gln Thr Leu Gly Leu Gln Asp

-35

-30

-25

aag cag agc acg tct agc acc cca caa gcc agc act cag agc aca gcc 414
Lys Gln Ser Thr Ser Ser Thr Pro Gln Ala Ser Thr Gln Ser Thr Ala

-20

-15

-10

cac att cga gtc aaa cgc tac cgc cag agc atg aac cag ggg tcc cgc 462
His Ile Arg Val Lys Arg Tyr Arg Gln Ser Met Asn Gln Gly Ser Arg

-5

-1 1

5

10

agc act gga tgc cgc ttt ggg acc tgc aca atg cag aaa ctg gct cac 510
Ser Thr Gly Cys Arg Phe Gly Thr Cys Thr Met Gln Lys Leu Ala His

15

20

25

cag atc tac cag ttt aca gac aaa gac aag gac ggc atg gcc ccc aga 558
Gln Ile Tyr Gln Phe Thr Asp Lys Asp Lys Asp Gly Met Ala Pro Arg

30

35

40

aac aag aic agc cct caa ggc tat ggc cgc cgg cgc cgg cgt tcc ctg 606
Asn Lys Ile Ser Pro Gln Gly Tyr Gly Arg Arg Arg Arg Arg Ser Leu

45

50

55

cca gag gtc ctc cga gcc cgg act gtg gag tcc tcc cag gag cag aca 654
Pro Glu Val Leu Arg Ala Arg Thr Val Glu Ser Ser Gln Glu Gln Thr

60

65

70

cac tca gct cca gcc tcc ccg gcg cac caa gac aic tcc aga gtc tct 702
His Ser Ala Pro Ala Ser Pro Ala His Gln Asp Ile Ser Arg Val Ser

75

80

85

90

agg tta taggtgcggg tggcagcatt gaacagtcgg gcgagtatcc caltggcgcc 758
Arg Leu

lgcggaaatca gagagcttcg caccctgagc ggactgagac aatctgcag agatctgcct 818
 ggcigcccci aggggaggca gaggaaccca agatcaagcc aggcicacgt cagaaccga 878
 gaattacagg ctgatactct ctccgggcag gggctgagc cactgccttg cccgctcata 938
 aaciggttiti ctcacggggc atacggctca ttacttacti gaactttcca aaacctgagc 998
 aggaaaagtg caatgctgt tatacagcca aaggtaacta tcataattaa gtttgttga 1058
 gtcaagaggti tttttttttt gtaacttcaa atatatagaa atattttgt acgttatata 1118
 ttgtattaa ggcattttaa agcgattata ttgtaccctt cccctatttt aagaagtga 1178
 tgcicagca aggtgtaagg ttgtttgggt cctgtgtgt gtgtgtgtgt gtgtgtgtgt 1238
 gtgtgtgtgt gtgtgtgtaa ggtggagagc gctgattac cgctgtgtga tgaagaaaaa 1298
 acattgtgtc ttctataatc tatttacata aaataigiga tctgggaaaa agcaaaccaa 1358
 taaactgtct caatgtct 1376

<210> 6
 <211> 185
 <212> PRT
 <213> Rattus norvegicus

<400> 6
 Met Lys Leu Val Ser Ile Ala Leu Met Leu Leu Gly Ser Leu Ala Val
 -90 -85 -80

Leu Gly Ala Asp Thr Ala Arg Leu Asp Thr Ser Ser Gln Phe Arg Lys
 -75 -70 -65

Lys Trp Asn Lys Trp Ala Leu Ser Arg Gly Lys Arg Glu Leu Gln Ala

-60

-55

-50

Ser Ser Ser Tyr Pro Thr Gly Leu Val Asp Glu Lys Thr Val Pro Thr

-45

-40

-35

-30

Gln Thr Leu Gly Leu Gln Asp Lys Gln Ser Thr Ser Ser Thr Pro Gln

-25

-20

-15

Ala Ser Thr Gln Ser Thr Ala His Ile Arg Val Lys Arg Tyr Arg Gln

-10

-5

-1 1

Ser Met Asn Gln Gly Ser Arg Ser Thr Gly Cys Arg Phe Gly Thr Cys

5

10

15

Thr Met Gln Lys Leu Ala His Gln Ile Tyr Gln Phe Thr Asp Lys Asp

20

25

30

35

Lys Asp Gly Met Ala Pro Arg Asn Lys Ile Ser Pro Gln Gly Tyr Gly

40

45

50

Arg Arg Arg Arg Ser Leu Pro Glu Val Leu Arg Ala Arg Thr Val

55

60

65

Glu Ser Ser Gln Glu Gln Thr His Ser Ala Pro Ala Ser Pro Ala His

70

75

80

Gln Asp Ile Ser Arg Val Ser Arg Leu

85

90

Please type a plus sign (+) inside this box → ☒Approved for use through 9/30/00. CMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR
DESIGN
PATENT APPLICATION
(37 CFR 1.63)**☒ Declaration
Submitted
with Initial
Filing
OR
☐ Declaration
Submitted after Initial
Filing (surcharge
(37 CFR 1.16 (e))
required)

Attorney Docket Number YAM 2 0013

First Named Inventor Toshihiko YANAGITA

COMPLETE IF KNOWN

Application Number /

Filing Date

Group Art Unit

Examiner Name

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

COMPOSITION FOR PROMOTING PASSIVE EXTENSION OF BLADDER SMOOTH
MUSCLE

the specification of which (Title of the invention)

☐ is attached hereto

OR

☒ was filed on (MM/DD/YYYY) 06/23/2000 as United States Application Number or PCT International

Application Number PCT/JP00/04166 and was amended on (MM/DD/YYYY) (Article 34)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

| Prior Foreign Application Number(s) | Country | Foreign Filing Date (MM/DD/YYYY) | Priority Not Claimed | Certified Copy Attached? | |
|-------------------------------------|---------|----------------------------------|--|--|---|
| | | | | YES | NO |
| 11-177549 | JAPAN | 06/23/1999 | <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> | <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> |

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

| Application Number(s) | Filing Date (MM/DD/YYYY) | |
|-----------------------|--------------------------|--|
| | | <input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto. |

(Page 1 of 2)

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☒ X

PTO/SB/01 (12-87)

Approved for use through 9/30/00, OMB 0651-0002

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**DECLARATION — Utility or Design Patent Application**

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT International application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

| U.S. Parent Application or PCT Parent Number | Parent Filing Date (MM/DD/YYYY) | Parent Patent Number (if applicable) |
|--|---------------------------------|--------------------------------------|
| | | |

☐ Additional U.S. or PCT International application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number

☒ Registered practitioner(s) name/registration number listed below

Place Customer Number Bar Code Label here

| Name | Registration Number | Name | Registration Number |
|------------------|---------------------|------|---------------------|
| Richard M. Klein | 33,000 | | |

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label ☒ Correspondence address below

| | | | | | |
|---------|--|-----------|----------------|-----|----------------|
| Name | Richard M. Klein | | | | |
| Address | FAY, SHARPE, FAGAN, MINNICH & McKEE, LLP | | | | |
| Address | 1100 Superior Avenue, Seventh Floor | | | | |
| City | Cleveland | State | OH | ZIP | 44114 |
| Country | U.S.A. | Telephone | (216) 861-5582 | Fax | (216) 241-1666 |

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such would false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

| | |
|--|------------------------|
| Given Name (first and middle (if any)) | Family Name or Surname |
| Toshihiko | YANAGITA |

| | | | | | | | |
|----------------------|--|-------|----------|---------|----------|-------------|-------|
| Inventor's Signature | Toshihiko Yanagita | | Date | 12/6/01 | | | |
| Residence: City | Miyazaki-shi | State | Miyazaki | Country | JAPAN | Citizenship | JAPAN |
| Post Office Address | 370 Banbelhouse A-401, 940, Oaza Tsunehisa | | | | | | |
| Post Office Address | | | | | | | |
| City | Miyazaki-shi | State | Miyazaki | ZIP | 880-0916 | Country | JAPAN |

☐ Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto